PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CNXC vs. ARCT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CNXC and ARCT is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

CNXC vs. ARCT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Concentrix Corporation (CNXC) and Arcturus Therapeutics Holdings Inc. (ARCT). The values are adjusted to include any dividend payments, if applicable.

-40.00%-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-26.66%
-29.69%
CNXC
ARCT

Key characteristics

Sharpe Ratio

CNXC:

-0.98

ARCT:

-0.65

Sortino Ratio

CNXC:

-1.35

ARCT:

-0.71

Omega Ratio

CNXC:

0.82

ARCT:

0.92

Calmar Ratio

CNXC:

-0.58

ARCT:

-0.55

Martin Ratio

CNXC:

-1.10

ARCT:

-1.09

Ulcer Index

CNXC:

43.19%

ARCT:

44.43%

Daily Std Dev

CNXC:

48.25%

ARCT:

74.38%

Max Drawdown

CNXC:

-81.19%

ARCT:

-90.09%

Current Drawdown

CNXC:

-75.28%

ARCT:

-86.42%

Fundamentals

Market Cap

CNXC:

$3.15B

ARCT:

$454.80M

EPS

CNXC:

$3.71

ARCT:

-$2.33

Total Revenue (TTM)

CNXC:

$7.17B

ARCT:

$117.39M

Gross Profit (TTM)

CNXC:

$2.22B

ARCT:

$124.76M

EBITDA (TTM)

CNXC:

$1.00B

ARCT:

-$51.84M

Returns By Period

In the year-to-date period, CNXC achieves a 13.15% return, which is significantly higher than ARCT's -1.06% return.


CNXC

YTD

13.15%

1M

20.95%

6M

-26.66%

1Y

-49.58%

5Y*

N/A

10Y*

N/A

ARCT

YTD

-1.06%

1M

8.46%

6M

-29.69%

1Y

-48.76%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CNXC vs. ARCT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNXC
The Risk-Adjusted Performance Rank of CNXC is 1010
Overall Rank
The Sharpe Ratio Rank of CNXC is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of CNXC is 66
Sortino Ratio Rank
The Omega Ratio Rank of CNXC is 66
Omega Ratio Rank
The Calmar Ratio Rank of CNXC is 1313
Calmar Ratio Rank
The Martin Ratio Rank of CNXC is 1919
Martin Ratio Rank

ARCT
The Risk-Adjusted Performance Rank of ARCT is 1616
Overall Rank
The Sharpe Ratio Rank of ARCT is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of ARCT is 1515
Sortino Ratio Rank
The Omega Ratio Rank of ARCT is 1717
Omega Ratio Rank
The Calmar Ratio Rank of ARCT is 1414
Calmar Ratio Rank
The Martin Ratio Rank of ARCT is 2020
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CNXC vs. ARCT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Concentrix Corporation (CNXC) and Arcturus Therapeutics Holdings Inc. (ARCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CNXC, currently valued at -0.98, compared to the broader market-2.000.002.004.00-0.98-0.65
The chart of Sortino ratio for CNXC, currently valued at -1.35, compared to the broader market-4.00-2.000.002.004.006.00-1.35-0.71
The chart of Omega ratio for CNXC, currently valued at 0.82, compared to the broader market0.501.001.502.000.820.92
The chart of Calmar ratio for CNXC, currently valued at -0.58, compared to the broader market0.002.004.006.00-0.58-0.55
The chart of Martin ratio for CNXC, currently valued at -1.10, compared to the broader market-10.000.0010.0020.0030.00-1.10-1.09
CNXC
ARCT

The current CNXC Sharpe Ratio is -0.98, which is lower than the ARCT Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of CNXC and ARCT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.00AugustSeptemberOctoberNovemberDecember2025
-0.98
-0.65
CNXC
ARCT

Dividends

CNXC vs. ARCT - Dividend Comparison

CNXC's dividend yield for the trailing twelve months is around 2.54%, while ARCT has not paid dividends to shareholders.


TTM2024202320222021
CNXC
Concentrix Corporation
2.54%2.87%1.15%0.77%0.14%
ARCT
Arcturus Therapeutics Holdings Inc.
0.00%0.00%0.00%0.00%0.00%

Drawdowns

CNXC vs. ARCT - Drawdown Comparison

The maximum CNXC drawdown since its inception was -81.19%, smaller than the maximum ARCT drawdown of -90.09%. Use the drawdown chart below to compare losses from any high point for CNXC and ARCT. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%-70.00%-65.00%AugustSeptemberOctoberNovemberDecember2025
-75.28%
-86.42%
CNXC
ARCT

Volatility

CNXC vs. ARCT - Volatility Comparison

The current volatility for Concentrix Corporation (CNXC) is 11.65%, while Arcturus Therapeutics Holdings Inc. (ARCT) has a volatility of 20.94%. This indicates that CNXC experiences smaller price fluctuations and is considered to be less risky than ARCT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
11.65%
20.94%
CNXC
ARCT

Financials

CNXC vs. ARCT - Financials Comparison

This section allows you to compare key financial metrics between Concentrix Corporation and Arcturus Therapeutics Holdings Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab